Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Myriad Genetics, Inc (NASDAQ: MYGN) closed at $12.41 in the last session, down -2.82% from day before closing price of $12.77. In other words, the price has decreased by -$2.82 from its previous closing price. On the day, 0.94 million shares were traded. MYGN stock price reached its highest trading level at $12.9899 during the session, while it also had its lowest trading level at $12.2.
Ratios:
We take a closer look at MYGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on December 10, 2024, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 09, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $30 to $21.
On September 19, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $32.Morgan Stanley initiated its Equal-Weight rating on September 19, 2024, with a $32 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1129746816 and an Enterprise Value of 1172947200. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.37 while its Price-to-Book (P/B) ratio in mrq is 1.54. Its current Enterprise Value per Revenue stands at 1.424 whereas that against EBITDA is -34.6.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.77, which has changed by -0.41901731 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $12.04. The 50-Day Moving Average of the stock is -11.92%, while the 200-Day Moving Average is calculated to be -42.62%.
Shares Statistics:
According to the various share statistics, MYGN traded on average about 1.06M shares per day over the past 3-months and 1257350 shares per day over the past 10 days. A total of 91.00M shares are outstanding, with a floating share count of 87.64M. Insiders hold about 3.73% of the company’s shares, while institutions hold 100.56% stake in the company. Shares short for MYGN as of 1736899200 were 4811940 with a Short Ratio of 4.52, compared to 1734048000 on 3349808. Therefore, it implies a Short% of Shares Outstanding of 4811940 and a Short% of Float of 7.39.
Earnings Estimates
As of right now, 15.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.15 and $0.12 for the fiscal current year, implying an average EPS of $0.13. EPS for the following year is $0.06, with 13.0 analysts recommending between $0.14 and -$0.1.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $210.4M. It ranges from a high estimate of $211.31M to a low estimate of $209.15M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $196.6MFor the next quarter, 7 analysts are estimating revenue of $209.62M. There is a high estimate of $216.62M for the next quarter, whereas the lowest estimate is $207.07M.
A total of 7 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $838.31M, while the lowest revenue estimate was $836.15M, resulting in an average revenue estimate of $837.4M. In the same quarter a year ago, actual revenue was $753.2MBased on 11 analysts’ estimates, the company’s revenue will be $863.81M in the next fiscal year. The high estimate is $881.5M and the low estimate is $843.51M.
